Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Buy
81
HALO Quote, Financials, Valuation and Earnings
Last price:
$79.45
Seasonality move
:
2.2%
Day range:
$77.55 - $81.19
52-week range:
$47.50 - $82.22
Dividend yield:
0%
P/E ratio:
16.70x
P/S ratio:
8.02x
P/B ratio:
18.54x
Volume:
1.7M
Avg. volume:
2M
1-year change:
35.54%
Market cap:
$9.3B
Revenue:
$1B
EPS (TTM):
$4.76
Analysts' Opinion
-
Consensus RatingHalozyme Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $78.00, Halozyme Therapeutics, Inc. has an estimated downside of -1.81% from its current price of $79.44.
-
Price Target UpsideAccording to analysts, the highest upside price target is $92.00 representing -100% upside increase from its current price of $79.44.
Fair Value
-
According to the consensus of 7 analysts, Halozyme Therapeutics, Inc. has -1.81% downside to fair value with a price target of $78.00 per share.
HALO vs. S&P 500
-
Over the past 5 trading days, Halozyme Therapeutics, Inc. has underperformed the S&P 500 by -0.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Halozyme Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Halozyme Therapeutics, Inc. has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Halozyme Therapeutics, Inc. reported revenues of $354.3M.
Earnings Growth
-
Halozyme Therapeutics, Inc. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Halozyme Therapeutics, Inc. reported earnings per share of $1.43.
Enterprise value:
10.2B
EV / Invested capital:
--
Price / LTM sales:
8.02x
EV / EBIT:
13.77x
EV / Revenue:
8.17x
PEG ratio (5yr expected):
0.29x
EV / Free cash flow:
16.85x
Price / Operating cash flow:
16.55x
Enterprise value / EBITDA:
12.39x
Gross Profit (TTM):
$979.7M
Return On Assets:
27.69%
Net Income Margin (TTM):
47.91%
Return On Equity:
139.43%
Return On Invested Capital:
30.69%
Operating Margin:
61.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $780.7M | $947.4M | $1.2B | $290.1M | $354.3M | |
| Gross Profit | $538M | $706.6M | $979.7M | $222.9M | $281.3M | |
| Operating Income | $312.4M | $477M | $737.4M | $163.2M | $217.9M | |
| EBITDA | $383.7M | $558.6M | $819.2M | $183.6M | $238.4M | |
| Diluted EPS | $1.87 | $3.02 | $4.76 | $1.05 | $1.43 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1B | $653.2M | $879M | $1.1B | $1.3B | |
| Total Assets | $1.2B | $1.9B | $1.9B | $2.1B | $2.2B | |
| Current Liabilities | $113.2M | $109.4M | $115.2M | $108.8M | $837.2M | |
| Total Liabilities | $903.7M | $1.8B | $1.6B | $1.7B | $1.7B | |
| Total Equity | $281.7M | $97M | $249.2M | $452.7M | $503.9M | |
| Total Debt | $875.7M | $1.5B | $1.5B | $1.5B | $1.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $368.7M | $403M | $611M | $115.4M | $178.6M | |
| Cash From Investing | -$90.4M | -$300.5M | $225.5M | -$167.5M | $201.6M | |
| Cash From Financing | -$151.7M | -$222.4M | -$571.1M | $18.6M | -$22.4M | |
| Free Cash Flow | $353.6M | $392.7M | $602.4M | $113.9M | $175.6M | |
HALO
Sector
Market Cap
$9.3B
$24M
Price % of 52-Week High
96.62%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
6.61%
-1.62%
1-Year Price Total Return
35.54%
-22.92%
Beta (5-Year)
0.968
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$79.27
200-day SMA
Buy
Level
$65.53
Bollinger Bands (100)
Buy
Level
65.24 - 74.22
Chaikin Money Flow
Buy
Level
94.7M
20-day SMA
Buy
Level
$74.85
Relative Strength Index (RSI14)
Buy
Level
62.78
ADX Line
Buy
Level
35.36
Williams %R
Neutral
Level
-21.821
50-day SMA
Buy
Level
$70.53
MACD (12, 26)
Buy
Level
2.50
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
289.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.0302)
Sell
CA Score
(Annual)
Level (-0.7533)
Buy
Beneish M-Score
(Annual)
Level (-2.3136)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (0.3542)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, HALO has received 4 Buy ratings 2 Hold ratings, and 1 Sell ratings. The HALO average analyst price target in the past 3 months is $78.00.
-
Where Will Halozyme Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Halozyme Therapeutics, Inc. share price will drop to $78.00 per share over the next 12 months.
-
What Do Analysts Say About Halozyme Therapeutics, Inc.?
Analysts are divided on their view about Halozyme Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Halozyme Therapeutics, Inc. is a Sell and believe this share price will rise from its current level to $58.00.
-
What Is Halozyme Therapeutics, Inc.'s Price Target?
The price target for Halozyme Therapeutics, Inc. over the next 1-year time period is forecast to be $78.00 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HALO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Halozyme Therapeutics, Inc. is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HALO?
You can purchase shares of Halozyme Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Halozyme Therapeutics, Inc. shares.
-
What Is The Halozyme Therapeutics, Inc. Share Price Today?
Halozyme Therapeutics, Inc. was last trading at $79.45 per share. This represents the most recent stock quote for Halozyme Therapeutics, Inc.. Yesterday, Halozyme Therapeutics, Inc. closed at $79.44 per share.
-
How To Buy Halozyme Therapeutics, Inc. Stock Online?
In order to purchase Halozyme Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get HALO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HALO
Sector
P/E ratio
16.70x
23.44x
PEG ratio
0.29x
-0.01x
P/B ratio
18.54x
1.73x
Price / LTM sales
8.02x
1.51x
Growth Metrics
HALO
Sector
Revenue growth
22.13%
3.31%
Earnings growth
36.06%
10.7%
Revenue (5-year growth)
38.96%
6.28%
Earnings forecast
$1.95
-$0.19
Profitability
HALO
Sector
Profitability FY 2024
$784.9M
$2.6M
Return on invested capital
30.69%
-33.62%
Return on assets
27.69%
-29.74%
Return on equity
139.43%
-39.33%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Feb
2
Balance Sheet
HALO
Sector
Total cash
$702M
$25M
Short term investments
$480.2M
$23.9M
Total assets
$2.2B
$71.9M
Long term debt
$1.5B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
